Furthermore, the FDA has classified CJC-1295 as a Category 2 bulk drug substanceindicating it presents "significant safety risks" for compounding
Pathologic fusion of the Ewing gene EWS to WT1 (t(11;22)(p13;q12)( EWS/WT1 )) has been shown to abrogate the tumour suppressor function of WT1 and to generate an oncogenic chimeric protein capable of binding and activating the IGF-1R promoter (Karnieli et al, 1996)
For example, the range for inter-individual variation in GSH levels is 2.6 mM, Table 1
Why it matters: Unlike growth hormone itself (which pulses throughout the day and is difficult to measure accurately), IGF-1 provides a reliable indication of your average growth hormone production over time
View on PubMed [PubMed] Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog (J Clin Endocrinol Metab, 2006) Clinical study in healthy adults demonstrating that CJC-1295, a long-acting GHRH analog, produced sustained, dose-dependent increases in GH and IGF-1 levels with a favorable safety profile over multiple doses
